Synonyms: Elunate® | Fruzaqla® | HMPL-013 | HMPL013
fruquintinib is an approved drug (China (2018), FDA (2023), EMA (2024))
Compound class:
Synthetic organic
Comment: Fruquintinib (HMPL-013) is a potent and selective inhibitor of VEGFR 1-3 tyrosine kinases, that was developed for antineoplastic activity [1] (preclinical data is reported in this reference).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
HMPL-013 shows only weak inhibition of RET (IC50 128nM), FGFR1 (IC50 181nM) and c-kit (IC50 458nM) kinases in a biochemical selectivity screen. Weak inhbition of FGFR1 was replicated in a cellular assay measuring bFGF stimulated FGFR1 phosphorylation [1]. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|